Rinvecalinase alfa

Protein / enzyme therapeutic

Also known as DM199

Phase 2/3underway

Evidence outlook · registrational

Acute Ischemic Stroke: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2026-12.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Acute Ischemic Stroke
Phase 2 (2)
Acute Ischemic Stroke
Other / comorbidity
NCT04123613 · DiaMedica Therapeutics Inc
2019-12-17 – 2022-03-16 · Kidney Diseases
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01845064 · DiaMedica Therapeutics Inc
2013-04 – 2014-11 · Diabetes Type 2
What this study did
Phase 1 (2)
Other / comorbidity
NCT03795389 · DiaMedica Therapeutics Inc
2019-02-12 – 2019-07-21 · Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT06875141 · DiaMedica Therapeutics Inc
2025-05 – 2025-05 · Pre-Eclampsia
What this study did

Competitive landscape

This drug's own stage for Acute Ischemic Stroke: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rinvecalinase Alfa: this drugPhase 2/3Protein / enzyme therapeuticTissue kallikrein-1 (KLK1)not yet gradedNo reviewed efficacy summary in this indication
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorReliable signal
NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants
Edaravone (TTYP01)Phase 3Small moleculeoxidative stressnot yet gradedNo reviewed efficacy summary in this indication
Apadamtase Alfa (Adzynma)Phase 2Protein / enzyme therapeuticADAMTS13not yet gradedNo reviewed efficacy summary in this indication
HRS-4029Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-7450Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-8829
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rinvecalinase alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2/3Acute Ischemic StrokeRecruiting
Est. primary completion 2026-12 · NCT05065216 · CT.gov ↗
What to watch

See the full readout calendar ↗